NCT01904123View on ClinicalTrials.gov

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions
Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaRecurrent Brain NeoplasmRecurrent GlioblastomaRecurrent Malignant Glioma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

STAT3 Inhibitor WP1066

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01904123 - STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | Biotech Hunter | Biotech Hunter